I have been doing some research to validate a claim I’m going to share with you guys. (But, it is worth re-checking and letting me know if you guys find anything to prove me wrong, we would all welcome other leads that match this criteria below 😅) The claim is: There is only ONE publicly traded small-cap company under $5B that was already profitable FY2025 and is currently on a trajectory to significantly MORE THAN DOUBLE Revenue and MORE THAN TRIPLE EPS, Gross Profit, EBDTA, net income and FCF by 2027E. Yes that’s right a single publicly traded company under $5B fulfills that criteria. And that trajectory is being validated through 2026 earnings and FY guidance so far. Here are some hints to make it easy: It is low beta. Has grown +245% YTD. Would stand strong in recession. Is run by less then 50 employees. Recently crushed Q2 earnings beating EPS estimates by triple digits. Raised guidance for BOY by 32%. Has not diluted investors or raised capital in over 6 years. It is an ABSOLUTE Moe favorite 😅 Can you guess which company this is? It’s $ETON Thanks for everyone who played along and made some great guesses.
200 views
27 Comments
Ian S@ian_s · 2d
My guess: a company this rare to find in a Blossom portfolio, treating diseases just as rare. 👍
Daisy Bear@daisy38 · 2d
I thought I’d missed the boat, but might have to have another look 👀?
Cornelius Osondu@collinomd2021 · 2d
@moe_on_margin The company is almost certainly Eton Pharmaceuticals (NASDAQ: ETON)
Eldon @selldon · 2d
If I know me, like I think I know me, I’m gonna not buy this one and I’m gonna regret it. 😜😂
See the full comment section 👀Sign up for the full Blossom experience!
